Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.75.
A number of equities research analysts recently weighed in on the stock. HC Wainwright upped their target price on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 9th. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Mizuho cut their price objective on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st. Finally, Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th.
View Our Latest Report on Autolus Therapeutics
Autolus Therapeutics Stock Down 0.3%
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The company had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. As a group, equities analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of AUTL. Invesco Ltd. grew its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after acquiring an additional 11,381 shares during the last quarter. Jane Street Group LLC raised its holdings in Autolus Therapeutics by 809.4% during the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after buying an additional 91,222 shares during the last quarter. Geode Capital Management LLC boosted its position in Autolus Therapeutics by 90.5% during the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after buying an additional 78,058 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after acquiring an additional 11,289 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Autolus Therapeutics by 2,891.7% in the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after acquiring an additional 942,540 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.
About Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.
Read More
- Five stocks we like better than Autolus Therapeutics
- Abivax: Wall Street Catches Up to the Data
- AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise?
- 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers
- Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
